Latest News
 16 June
PolyTherics Ltd and Alligator Bioscience AB announce strategic collaboration for optimisation of next generation biopharmaceuticals
28 May
Secretary of State John Denham visits PolyTherics
 27 May
Novel Approach to Drug Insolubility strengthens PolyTherics patent estate
 More news
Sitemap
TheraPEG ™
Click to view or download brochure on TheraPEG ™ technology
|
|
PolyTherics is a company dedicated to using biomedical polymers to optimise pharmaceuticals, in particular biopharmaceuticals, for the treatment and cure of the world's most important diseases.
PolyTherics' most advanced programmes are designed to exploit TheraPEG ™ technology, an innovative, patent protected approach to the PEGylation of therapeutic proteins and antibody fragments. Through the targeted attachment of PEG via naturally occurring disulfide bonds within proteins, biochemical and biophysical properties can be altered without compromising biological activity.
Beyond targeted PEGylation, PolyTherics has developed proprietary polymer-based technologies for application to both small molecules and large proteins, to create a broad portfolio of improved medicines.
|
Sitemap | Privacy Policy | Terms of Use
